Positive data presented Friday, particularly the statistically significant survival benefit favoring patients treated with rindopepimut, has Celldex planning -- cautiously -- for a conversation with the FDA about accelerated approval.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
J&J is paying $35 million upfront to Geron for rights to the drug.
An analysis of results from Oxigene's phase II study of fosbretabulin plus Avastin in recurrent ovarian cancer.
Here's a quick sketch of the Wall Street gossip mill emerging from the 'Liver Meeting.'
A Dendreon agreement calls for a financial restructuring of the company in which the bondholders will receive equity for the debt owed, potentially wiping out current equity shareholders.
Based on promising results from a small study, Sage expects to start a larger phase III study of its anti-seizure drug next year.
A triple therapy combining two experimental Merck drugs with Gilead's Sovaldi yielded interim hepatitis C cure rates for ranging from 80% to 87% following six to eight weeks of treatment.
A deeply flawed FDA advisory panel voted to support Rockwell's iron replacement therapy for dialysis. FDA still must decide if the product is approvable.
Salix Pharmaceuticals has been rocked by an accounting scandal involving inventory levels of its key gastrointestinal drugs, forcing the company to cut financial forecasts for the rest of the year.